Bispecific antibodies – mechanisms, evidence and future role

Bispecific antibodies represent an important therapeutic advance in the treatment of aggressive B-cell lymphomas. Through the targeted recruitment of T cells against malignant B cells, they open up new options for patients who no longer respond to established therapies. Their rapid clinical use raises the question of what role they will play in the future standard of care.